The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Dienstag, N Engl J Med 359(14):1486-1500 October 2, 2008.

Correspondence
PreviousPrevious
Volume 360:304-306 January 15, 2009 Number 3
NextNext

Hepatitis B Virus Infection

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Dienstag, J. L.
-PubMed Citation
To the Editor: In his review article on drug therapy for hepatitis B virus (HBV) infection, Dienstag (Oct. 2 issue)1 does not mention the use of prophylactic antiviral drugs in patients treated with chemotherapy, stem-cell transplantation, or immunosuppressive agents. Reactivation of hepatitis B (including death2) has been described in patients who were anti–hepatitis B core–positive and hepatitis B surface antigen (HBsAg)–negative.3 Several guidelines and discussions4,5 on this topic have been published, recommending lamivudine as prophylaxis. This is an important issue that should have been included in the review article because there is an increasing population of patients who are . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.